94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1563797
This article is part of the Research Topic Decoding the Epigenetic Landscape: Elucidating Cancer Pathology and Identifying Novel Therapeutic Targets View all 17 articles
Characteristic Analysis of Adverse Reactions of Histone Deacetylase Inhibitors Based on WHO-VigiAccess
Provisionally accepted- 1 Central Laboratory, NanYang Central Hospital, Nanyang, China
- 2 School of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China
- 3 Department of Dermatology, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, China
- 4 Department of Preventive Dentistry, School of Stomatology, The Fourth Military Medical University, Xian, China
- 5 Health Management Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China
- 6 Department of Oncology, Nanyang central Hospital, Nanyang, Nanyang, China
Background: This study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO). Furthermore, it compared the ADR profiles of three different drugs to identify the one with the lowest individualized risk for patients.Data on adverse events of HDAC Inhibitors was retrieved from WHO-VigiAccess on January 6, 2025. We obtained data on age, gender, reporting year, and continent.Descriptive data related were calculated using Excel 2021. In this study, we used Excel software to analyze the characteristics of those who were harmed due toCurrent comparative observational studies of these inhibitors indicate that there are both common and specific adverse reactions reported in the ADR data received by the WHO for these medications. Clinicians should enhance the rational use of these drugs by considering the characteristics of the reported ADRs.
Keywords: Histone deacetylase inhibitor, adverse drug reactions, Chidamide, Romidepsin, vorinostat, WHO-Vigiaccess
Received: 20 Jan 2025; Accepted: 27 Feb 2025.
Copyright: © 2025 Yin, Liu, Li, Feng, Lin and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yumeng Lin, Health Management Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China
Zhongyu Qu, Department of Oncology, Nanyang central Hospital, Nanyang, Nanyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.